Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Dipnech: Clinical Characteristics of an International Case Series
O'Brien, H., O’Callaghan, Michael , Penugonda, M., Almeamar, Hussein , Samhouri, Bilal F. , Veltkamp, Marcel , Manali, Effrosyni D. , Lazaratou, A., Papiris, Spiridon, Carr, Laurie, Kolilekas, Lykourgos , Daniil, Z., Hernández‐González, Fernanda , Torres, J. Sellares, O’Shea, Diarmuid , Murphy, D.J., Fabre, Aurélie , Forde, Sarah H. , Diesler, Rémi , Ryu, Jay H. , Bonella, Francesco , Cottin, Vincent , Taillé, Camille , McCormack, Francis X. , Gupta, Nishant , Strosberg, Jonathan , Lococo, Filippo , Harari, Sergio , Bouros, Demosthenes , Dimeas, Ilias E. , Torres, J. Sellares, Spagnolo, Paolo , Franciosi, Alessandro N. , Crowley, Rachel Katherine , O’Toole, Dermot , Byrne, Adam J. , Keane, Michael P. , Fournel, Ludovic , McCarthy, Cormac

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1804-A1804

10.1164/ajrccm.2025.211.abstracts.a1804 Get It

Abstract Rationale: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a pulmonary condition characterised by neuroendocrine cell proliferation along respiratory bronchioles resulting in tumourlet formation which may progress to pulmonary carcinoid. DIPNECH is a rare and under-recognised condition that predominantly affects females, with an estimated worldwide incidence of 5-6 people per million population. Given it's rarity and the poor understanding around the pathogenesis and treatment of this condition, we undertook the largest international case series to date of DIPNECH patients. We aim to further characterise this patient cohort to better understand the clinical features, identify common pulmonary function test (PFT) patterns and radiographic findings and describe current treatment practices. Methods: We collated data from 17 centres across 8 different countries comprising a total of 258 patients. Data collected included patient demographics, smoking history, symptoms, co-morbidities, pathological diagnosis, imaging findings, PFT pattern and therapies. Results: In total 258 patients were identified. The median age was 65 (SD+/- 10.6). 241 (93%) were female. 39% (n= 94/243) were ex-smokers. 79% (n=186/234) of patients reported pulmonary symptoms with cough being the most common symptom reported in 81% (n=151/186) of patients. Many patients were polysymptomatic, with cough and dyspnoea being the most common combination of symptoms described. (50.54%; n=94/186). Complete spirometry pattern was documented for 180 patients (69.78%) with an obstructive pattern being the most commonly observed (n=76/180; 42%). 27.5% (n=41/139) had clinically significant FEV1 reversibility post bronchodilator administration. Pathology specimens were available in 219 cases. Most common pathological features were neuroendocrine hyperplasia which was observed in 75% (n=165/219) and tumourlets in 74% (n=162/219) of cases. Carcinoid, either typical or atypical, was observed in 64% (n=141/219) of samples. 252 patients had computed tomography (CT) imaging performed. Pulmonary nodules were the most common feature identified in 99.60% of cases (248/250). Mosaic attenuation (69.30%; n=50/173) and airway dilatation (28.90%; n=50/173) were also frequently reported. There was no significant correlation between symptoms (cough, dyspnoea, wheeze) and airway dilatation (p=0.496), mosaic attenuation (p=0.496) and PFT pattern (p=0.837). There was a significant association between presence of symptoms and mosaic attenuation on CT (p=0.003). Conclusions: DIPNECH, while a rare disorder, is understudied. This international case series is the largest performed to date and highlights the complexity in management of these patients.
Association of Mood or Affect With Lung Function and All-cause Mortality in Fibrotic Interstitial Lung Disease
Peterson, U.D., Moua, T., Roy, M.J.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1731-A1731

10.1164/ajrccm.2025.211.abstracts.a1731 Get It

Abstract Rationale: Patients with fibrotic interstitial lung disease (F-ILD) often report high symptom burden with significant impact on their health-related quality of life. Self-reported disease experience may be unique or difficult to quantify yet have implications for functional and survival outcomes. We hypothesize that self-reported mood or affect may be associated with changes in lung function and predict mortality. Methods: This is a post-hoc analysis of a prospective cross-sectional study assessing changes in patient-reported outcome measures (PROM), lung function, and mortality incidence in patients with f-ILD. Serial measures of lung function and PROMs (baseline, 3, 6, and 12 months) were obtained over a 3-year period. The Positive and Negative Affect Scale (PANAS) is a 20-item questionnaire reflecting acute or immediate mood at the time of assessment, with higher scores for each domain highlighting greater positive or negative affect. A ratio of the Positive over the Negative score was used to summarize overall mood, with higher ratios reflecting more positive affect. PANAS scores at the time of lung function measures were assessed for their association with percent predicted forced vital capacity (FVC%) and diffusion capacity for carbon monoxide (DLCO%). Baseline PANAS scores were used to predict of all-cause mortality over the three-year study period. Results: One-hundred and eighty seven patients were included (mean age 69, female 37%, non-IPF f-ILD 67%). PANAS Negative scores were higher (16.9 vs 14.5, P = 0.01)with lower PANAS Ratio scores (2.5 vs 2.2, P = 0.08) in patients with non-IPF f-ILD, suggesting more negative affect or mood. A mixed effects model for repeated measures with each subject as a random effect found changes in the PANAS Positive score (point estimate 0.16, (0.01-0.32), P = 0.038) and Ratio score (1.43 (0.15-2.72), P = 0.029) were associated with changes in FVC% but not DLCO%. Baseline PANAS Negative (hazard ratios 1.06 (1.02-1.10), P = 0.002) and Ratio scores (HR 0.76 (0.61-0.95), P = 0.014) after adjusting for age, sex, FVC%, and diagnosis type (IPF vs non-IPF), were associated with increased all-cause mortality. Conclusions: Measured changes in self-reported mood or affect appear to be associated with changes in lung function and predict all-cause mortality. Direct assessments of patient disease experience may not only reflect symptom burden or disease progression but serve as targets of comprehensive management strategies or correlates of treatment efficacy given their potential association with lung function and survival.
Using Computer-aided Lung Informatics for Pathology Evaluation and Ratings (CALIPER) to Differentiate Immune Checkpoint Inhibitor (ICI) and Radiation Pneumonitis From Infectious Pneumonitis
Karanam, V., LeMaheiu, A., Bartholmai, Brian J. , Egan, Michael

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1716-A1716

10.1164/ajrccm.2025.211.abstracts.a1716 Get It

Abstract Rationale Immune checkpoint inhibitors (ICI) have become standard care for many cancers. Their mechanism of action mediates immune related adverse events including ICI pneumonitis. Diagnosis of this is difficult to differentiate from infectious and radiation pneumonitis as it is a diagnosis of exclusion often requiring bronchoscopy and imaging interpreted by expert radiologists. This study investigates the use of CALIPER, a computer-aided lung informatics program, in identifying differences between Computed Tomography (CT) patterns in ICI, radiation, and infectious pneumonitis that may aid in diagnosis noninvasively. Methods CT images of ten patients with ICI pneumonitis, ten patients with infectious pneumonitis, and nine patients with radiation pneumonitis, all diagnosed by clinical expertise and evaluation with bronchoalveolar lavage, were analyzed with CALIPER. CALIPER classified each CT voxel into either vessel-related structures (VRS), normal, mild low-attenuation area (LAA), moderate LAA, severe LAA, reticular (R), honeycomb (HC) or ground-glass (GG) features. Each lung was divided into upper, middle, and lower lobes. Exploratory analyses explored the relationship between CALIPER components and diagnosis, comparing ICI and radiation pneumonitis with infectious pneumonitis. Diagnosis was analyzed using multinomial logistic regression adjusted for presence of pleural effusion. Additionally, diagnosis was assessed as infectious versus a pooled group of radiation and ICI pneumonitis and analyzed using logistic regression adjusted for pleural effusion. Due to the exploratory nature of analysis, no correction was applied for multiplicity of testing. Results Twenty-nine patients were analyzed. ICI pneumonitis patients had less moderate low attenuation in the left upper (p = 0.016) and middle peripheral lung (p = 0.038), and radiation pneumonitis patients had less moderate low attenuation in the left upper peripheral lung (p = 0.031). When comparing the pooled group of ICI and radiation pneumonitis images with infectious pneumonitis, there was more moderate LAA in left upper (0.012) and middle (0.034) peripheral lung in the pooled group compared to infectious pneumonitis. There was no association with VRS, GG, HC, R, mild, or severe LAA patterns. Conclusions Although areas of moderate low attenuation were more prevalent for infectious pneumonitis, these results taken in the context of low sample size, exploratory analysis, and lack of clinical reasoning to support these findings make them likely insignificant. Based on this limited exploratory analysis, it is unlikely that we can solely use CALIPER as noninvasive evaluation to differentiate radiation and ICI pneumonitis from infectious pneumonitis. This highlights the need for a more robust program to aid in noninvasive diagnosis.
18F-FDG Positron Emission Tomography Findings in Patients With Lymphoid Interstitial Pneumonia
Alaws, Hossny, Deleveaux, S., Patel, Neil , Soto, Jose Soto

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1712-A1712

10.1164/ajrccm.2025.211.abstracts.a1712 Get It

Abstract Rationale: Lymphoid Interstitial Pneumonia (LIP) is a rare interstitial lung disease characterized as a benign lymphoproliferative pulmonary condition. It is often associated with autoimmune conditions such as Sjögren's syndrome, immune dysregulatory syndromes, and common variable immunodeficiency. The incidence and prevalence of LIP remain unclear. While fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) findings have been documented for various diffuse parenchymal lung diseases, data specific to LIP is limited. This study aims to assess the utility of PET/CT in the evaluation of malignancy in patients with LIP, in addition to describing PET/CT findings in patients with known LIP who underwent PET/CT for any reason. Methods: This retrospective study involved a reviewof electronic medical records within the Mayo Clinic Enterprise to identify patients with an established diagnosis of LIP who had undergone PET/CT. Using ICD code J84.2, we identified patients with a diagnosis of LIP, and further selected for those who had undergone PET/CT between 2009 and 2023. We analyzed descriptive statistics, including the mean and prevalence of common PET/CT findings. Results: We identified 10 patients, all of whom had anestablished expert diagnosis of LIP and had undergone PET/CT for any reason. The mean age was 66 years, and all patients were female. Six of the ten patients (60%) underwent a lung biopsy, and six (60%) exhibited FDG uptake in the lungs, with maximum standard uptake value (SUVmax) uptake ranging from 2.0 to 8.2. Six of the imaging studies (60%) showed abnormal FDG uptake in one or more lymph nodes, with SUV maximum ranging from 2.4 to 7.8, and four (40%) demonstrated extrapulmonary FDG uptake. Four patients were diagnosed with a malignancy, the majority being MALT, with one being lung squamous cell carcinoma (SCC). Conclusion: Given the rarity of LIP, there is limiteddata on the utility and findings of PET/CT in these patients. Our study reveals that in patients with LIP, despite abnormal parenchyma in the background of inflammatory disease, malignancy was still likely in abnormally hypermetabolic regions. In this study, lymphoma was the most common malignancy isolated in patients with LIP. Nonetheless, malignancy other than lymphoma can occur, namely squamous cell carcinoma (SCC), and PET positivity can occur in LIP patients even in the absence of tissue proven malignancy. In patients with LIP, SUVmax does not appear to be a differentiating factor between those later diagnosed with lymphoma (SUVmax 2.0-8.2) and SCC (SUVmax=3.1).
Tracheostomy Care: A Hospital's Dilemma
Noland, D., Fouty, Brian, Petrossian, R., Yendrapalli, U. , Grannum, M.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1533-A1533

10.1164/ajrccm.2025.211.abstracts.a1533 Get It

Abstract Rationale: Tracheostomies are commonly placed to facilitate weaning from ventilators in ICU patients who fail extubation. Once these patients are successfully weaned from mechanical ventilation and transferred out of the ICU however, management of the tracheostomies are frequently left to the floor teams that are less experienced in managing them. This can delay downsizing/removing tracheostomies when appropriate or in exchanging them when they cannot be safely removed. This report details the number and type of patients with tracheostomies and describes their tracheostomy management after placement.in a small university hospital that did not have a dedicated tracheostomy team. Methods: We reviewed the charts of all patients with tracheostomies who were in the hospital on a single day (7/22/2024). Patients were categorized based on which service placed the initial trach, the reason for the tracheostomy placement, the time from the initial trach placement, and the most recent exchange date. Results: Twelve patients with tracheostomies were in the hospital on that day (4% of all hospitalized patients); six were still in the ICU and 6 were on the floor. The time from initial tracheostomy placement ranged from 10 days to 2.5 years. The primary indications for tracheostomy included respiratory failure (n=5), cerebrovascular accidents (CVA) (n=4), and trauma (n=3). Eight tracheostomies were placed by the Surgery/Trauma service, three by the ENT service, and one by an outside hospital. At the time of data collection 5 of the 12 patients had not yet received a first trach exchange with an average time from tracheostomy placement of >20 days. Three of the 12 patients had had their trach downsized at least once. At least 4 patients had not had a documented tracheostomy exchange for at least 2 months. Conclusion: Our findings emphasize the diverse clinical situations requiring tracheostomy and their impact on patient care in and out of the ICU. The study highlights the importance of continuous assessment throughout a patient's hospital stay. In at least four cases, tracheostomy exchange intervals exceeded the recommended monthly timeframe. Research indicates that tracheostomy teams improve patient safety and outcomes through standardized protocols, suggesting a need for further investigation into team dynamics and their role in recovery.
Association of Obesity With Mortality, ARDS, and Thromboembolism in ICU Patients on Prolonged Ventilation
LOHANA, ABHI , Versha, Fnu, Kumar, B., Khawar, Muhammad Umair , Patel, Viral , Akbar, Usman Ali , Chander, Subhash

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1504-A1504

10.1164/ajrccm.2025.211.abstracts.a1504 Get It

Abstract Introduction: Obesity's increasing prevalence significantly impacts Intensive Care Unit (ICU) patient outcomes, especially for those requiring prolonged mechanical ventilation. This study investigates the effect of Body Mass Index (BMI) on mortality and complications—such as acute respiratory distress syndrome (ARDS), pulmonary embolism (PE), and deep vein thrombosis (DVT)—in ICU patients intubated for over 96 hours. Methods: We conducted a retrospective cohort study using the TriNetX database to identify patient populations with relevant ICD codes. Patients who had received anticoagulation and had been on mechanical ventilation for more than 96 hours were included. Cohort 1 consisted of patients with a BMI of 30-44.9 kg/m² (n = 70,379), and Cohort 2 included patients with a BMI of 18.5-29.9 kg/m² (n = 111,054). Both cohorts were matched using propensity score matching (PSM), resulting in balanced groups of 47,233 patients. The mean age was 64.3 ± 15.1 years in Cohort 1 and 64.5 ± 16.5 years in Cohort 2, with a male predominance of 57.9% in both cohorts after matching. Outcomes (mortality, PE, DVT, and ARDS) were identified using ICD-10 codes and analyzed on Days 14, 30, and 90. Results: Higher BMI was associated with increased all-cause mortality across all measured time points. By Day 14, mortality was 23.0% in Cohort 1 versus 19.2% in Cohort 2 (RiskRatio [RR]: 1.196; 95% CI: 1.166-1.226). By Day 90, mortality reached 37.6% in Cohort 1 compared to 32.6% in Cohort 2 (RR: 1.151; 95% CI: 1.132-1.171). Additionally, the risk of developing ARDS was higher in Cohort 1, with statistically significant risk ratios observed on Day 14 (RR: 1.117; 95% CI: 1.020-1.222) and Day 30 (RR: 1.094; 95%CI: 1.010-1.186). PE risk in Cohort 1 significantly increased by Day 30 (RR: 1.119; 95% CI: 1.008-1.243), while DVT risk was also elevated in Cohort 1 at both Day 14 (RR:1.140; 95% CI: 1.037-1.253) and Day 30 (RR: 1.129; 95% CI: 1.040-1.224). Conclusion: Higher BMI in mechanically ventilated ICU patients intubated for more than 96 hours is associated with increased mortality and a higher incidence of complications, including ARDS, PE, and DVT. This study contributes to our understanding of BMI's impact on ICU outcomes, highlighting critical areas for improved clinical management in this population and the need for targeted interventions in obese ICU patients, such as optimized respiratory support and monitoring for thromboemboliccomplications.
Study of Soy Isoflavones (SOYA) Responder Analysis Among Patients Who Have 4G4G/4G5G Serine Protease Inhibitor Family E Member 1 (SERPINE1) Genotypes
Fowler, John R. , Cardet, J.C., Mhaskar, Rahul , Baptist, Alan P. , Dixon, Anne E. , Hanania, N.A., Israel, Elliot , Garrow, O.J., Moy, James N., Riley, Isaretta , Wang, J.G., Fowler, J., Nguyen, D.T., Casale, Thomas B. , Chiarella, Sergio E. , Garrow, Olivia Johnson, Nyenhuis, Sharmilee Maria , Smith, Lewis J. , Wu, Timothy , Cho, Seong , Kumar, Rajesh

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1344-A1344

10.1164/ajrccm.2025.211.abstracts.a1344 Get It

Abstract RATIONALE: 4G4G/4G5G SERPINE1 genotypes produce high concentrations of plasminogen activator inhibitor-1 and are associated with worse asthma outcomes. A secondary analysis of the American Lung Association (ALA) SOYA trial showed that soy isoflavones significantly reduced asthma exacerbations versus placebo among patients with 4G4G/4G5G SERPINE1 genotypes. We hypothesized that baseline characteristics predict optimal responders to soy isoflavones among this subgroup. METHODS: ALA-SOYA was a randomized controlled trial that tested the efficacy of soy isoflavones vs. placebo for reducing asthma exacerbations among adolescents and adults with symptomatic asthma. In this responder analysis among participants with 4G4G/4G5G SERPINE1 genotypes, baseline demographic and clinical characteristics were tested for effect modification of the treatment assignment (soy/placebo) on the primary outcome of annualized number of asthma exacerbations using interaction terms in negative binomial regression models, with a significance threshold of p-interaction=0.15. RESULTS: Data were available for n=168 participants. Soy reduced the annualized number of asthma exacerbations relative to placebo among patients with 4G4G/4G5G SERPINE1 genotypes (incident rate ratio (IRR)=0.37, 95% confidence interval (CI): 0.15-0.90, p=0.028). Self-reported adherence to baseline controller therapy was the only significant effect modifier of this association (interaction p=0.115), with those using inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA) controller therapy at least twice weekly experiencing reductions in asthma exacerbations with soy versus placebo (IRR = 0.25, 95% CI: 0.09-0.69; p= 0.007) but not among those using ICS/LABA controller therapy less frequently (IRR = 1.33, 95% CI: 0.22-8.02; p= 0.757). CONCLUSION: Soy isoflavones reduce asthma exacerbations among patients with the 4G4G/4G5G SERPINE1 genotypes and are most effective in those with greater adherence to asthma controller therapy regimens.
Albuterol-Budesonide Treatment in Acute Airway Obstruction: Patient Selection for the ALTA Study
Panettieri, Reynold A. , Wanner, A., Lipworth, BJ, Israel, E. , Meyers, Deborah A. , Ortega, Victor E. , Keith, M., Burnette, A.F., Gilbert, Ileen , Bleecker, Eugene R. , Akuthota, Praveen , Clarke, Graham W.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1317-A1317

10.1164/ajrccm.2025.211.abstracts.a1317 Get It

Abstract RATIONALE: Albuterol-budesonide 180/160 µg is indicated in the US for as-needed treatment or prevention of bronchoconstriction and to reduce risk of exacerbations in patients ≥18 years old with asthma. The objective of the ALbuterol-budesonide Treatment in Acute airway obstruction (ALTA) study (NCT05555290) is to assess comparative efficacy, safety, and mechanisms of action of albuterol-budesonide 180/160 µg versus albuterol 180 µg in treating and preventing bronchoconstriction. This report describes the clinical profiles of patients meeting criteria for randomization into the trial. METHODS: ALTA is a phase 3b, multicenter, randomized, double-blind, 2-period, cross-over study evaluating the effects of repetitive dosing of albuterol-budesonide 180/160 µg versus albuterol 180 µg for treating adults treated as intermittent asthma and experiencing acute airway obstruction induced by repeated mannitol challenges. Inclusion criteria evaluated during screening include asthma diagnosis ≥6 months, prescribed and utilizing albuterol as the only asthma treatment for ≥4 weeks, pre-bronchodilator FEV1 ≥1.50 L and FEV1 ≥60% to <90% predicted, and positive response to a mannitol challenge (decrease in FEV1≥15% at ≤635 mg cumulative mannitol dose). Exclusion criteria include clinically significant lung disease other than asthma; any smoking in the prior 6 months or ≥10 pack-year smoking history; or a clinical encounter for asthma worsening within the past 4 weeks. RESULTS: Thus far, 84 patients have met the criteria for randomization into ALTA. Mean(SD) age=44.9(13.7) years, 56.0% female, 40.5% African American, 9.5% Hispanic/Latino. Clinical characteristics include 10.7% with 1 prior-year severe exacerbation; mean(SD) fractional exhaled nitric oxide=37.0(37.4) ppb; mean(SD) baseline pre-bronchodilator FEV1=2.464(0.538) L; mean(SD) baseline percent predicted FEV1=76.7(7.9)%; mean(SD) % fall in FEV1 with mannitol challenge=22.1(7.3)% at a mean(SD) cumulative mannitol dose of 146.4(176.3) mg. Despite being treated for intermittent asthma, based upon symptoms, lung function, and exacerbation history, no patients met NAEPP 2007 criteria for intermittent disease, and 13.1% fell into the mild, 78.6% moderate, and 8.3% severe persistent asthma categories (Figure). With respect to asthma control, as measured by Asthma Impairment and Risk Questionnaire scores, 60.7% had well-controlled, 20.2% not well-controlled, and 19.1% very poorly controlled disease. CONCLUSION: The baseline characteristics of patients in the ALTA study reveal that patients treated as intermittent asthma exhibit heterogeneity in clinical characteristics, airway hyper-reactivity, T2 inflammation, and disease severity and control. Additional genomic and biomarker data are forthcoming and altogether will provide an opportunity to address the mechanism of albuterol and budesonide interactions in a broad spectrum of asthma phenotypes.
A Screening Tool to Predict Post-intensive Care Syndrome (PICS) in the Critically Ill
Philbrick, Kemuel L. , Clark, Mike , Harris, Burton H., Cornelius, P., Sonsalla, K., Karnatovskaia, Lioudmila V. , Valle, Kathryn T. del , Harris, B.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1170-A1170

10.1164/ajrccm.2025.211.abstracts.a1170 Get It

Abstract RATIONALE: Many ICU patients experience physical, psychological, and cognitive impairments following resolution of critical illness, collectively referred to as post-intensive care syndrome (PICS). PICS has become widely recognized within the critical care field, but how to screen for PICS does not currently have consensus. Development of a validated, concise PICS screening tool would allow for rapid identification of this vulnerable and understudied population. Therefore, this study's goal was to develop and evaluate a screening tool to identify patients at risk for PICS. METHODS: We performed a prospective cohort study in a quaternary academic hospital. We included adults ≥ 18 years old with ≥48 hours spent in an ICU. Exclusion criteria were admission for suicide attempt, severe cognitive impairment/dementia, life expectancy <3 months, and non-English speaking. We assessed mental, cognitive, and physical function following ICU discharge and at 3 months using Hospital Anxiety and Depression Scale, Impact of Event Scale-Revised, Montreal Cognitive Assessment-blind, and Barthel Index. Our team, including critical care physicians, psychiatrists, psychologists, physical and occupational therapists, and nurses, developed a brief 15-item PICS screening tool (5 questions/domain). This tool was administered after patients were discharged from ICU stay to general care to assess its effectiveness in predicting impairments in all 3 domains at discharge and again at three months after hospital discharge, in comparison to previously mentioned validated questionnaires. Youden index statistical methods were used to determine potential “cutoff” values (scores) for the tool to maximize sensitivity and specificity. RESULTS: A total of 194 patients from 6 ICUs were recruited and completed the initial questionnaire, and 109 (56%) patients completed 3-month follow-up. Median age was 65 years (IQR 57-72) and 49% (95/194) were female. Screening tool is depicted in Figure 1. Overall, the screening tool weakly-to-moderately correlated with continuous outcomes of the validated measures upon ICU discharge and 3-month follow-up. When evaluating sensitivity and specificity for individual domains, the tool had an area under the receiver operating curve of >0.7 for the following domains: cognitive, anxiety, and physical impairments, indicating moderate-to-good sensitivity and specificity. CONCLUSIONS: This PICS screening tool was correlated with validated measures of PICS upon ICU discharge and at 3-month follow-up for all three domains. The tool's strength lies in its concise nature, making it easier for those caring for this patient population to screen for long-term effects of an ICU stay. Our proposed next step is validation of the PICS screening tool in an external cohort.
Paclitaxel-coated Balloon Dilation in Recurrent Airway Stenosis
ORTIZ-JAIMES, GABRIEL E, Mullon, John J., Nelson, Darlene R. , Reisenauer, Janani , Midthun, David E. , Edell, Eric S. , Anderson, D.K., Kern, R., Vargas-Brochero, Maria J. , Kern, Ryan

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1147-A1147

10.1164/ajrccm.2025.211.abstracts.a1147 Get It

Abstract Rationale: Airway-stenosing disease is a significant clinical problem in multiple populations. While the immediate endoscopic and clinical response to bronchoscopic interventions are high, rates of clinically significant recurrence are elevated, and often require multiple and frequent reinterventions. Newer strategies to prevent recurrence of central and proximal airway stenosis are needed. Methods: Retrospective review of bronchoscopic balloon bronchoplasties performed at the Mayo Clinic utilizing paclitaxel coated balloons (PCB) in 2023-2024 for recurrent airway stenosis. IN.PACT Admiral and AV balloons (sizes 5-12 mm, 3.5 mcg/mm2 paclitaxel dose) were used with an inflation time of 2-3 minutes. Procedural success was defined as <50% airway stenosis or resolution of the procedural indication. Reintervention was considered only if a therapeutic bronchoscopy was subsequently required to address the same lesion treated with PCB. Only patients with follow-ups >90 days were included in the reintervention inter-procedural time analysis. Results: Thirty-three procedures were performed in 18 patients. Seventeen (51%) for lung transplantation-associated stenosis (29% anastomotic/perianastomotic, 76% lobar and segmental stenoses), 8 (24%) for granulomatous polyangiitis-associated stenosis, 3 for postintubation tracheal stenosis and 2 for chemical/pill injury. Eighteen cases (54%) utilized an additional dilation modality (12 non-coated balloon dilation, 4 rigid dilation), 5 spray cryotherapy, 6 other ablative therapies (4 CO2-laser, 2 electrocautery cuts), and 6 received an airway stent during the same procedure. 57% percent of interventions occurred in the lobar, 27% mainstem/bronchus intermedius, 9% tracheal, 7% segmental airways. Thirty-one (93%) cases had a satisfactory initial endoscopic result. The median number of bronchoscopic therapeutic interventions required before the use pf PCB was 5 (IQR 2.5-11.5), which significantly decreased to 0.1 (IQR 0-1, range 0-9) after PCB (p <0.001). The reintervention-free survival significantly increased after PCB dilation from a median 35 days (IQR 28.7-80.5) to 132 days (IQR 64-197; p=0.004). Twenty-one cases required subsequent bronchoscopies, sixteen (76%) of which demonstrated improvement in lesion severity when compared to the results of prior interventions. Only 16 (48%) required therapeutically addressing the same lesion. Only 2 minor complications occurred (6%, self-limited bleeding and unplanned admission), none related to paclitaxel use. Six-month mortality was 3% from an unrelated cause. Conclusions: The locoregional antiproliferative effects of paclitaxel show promise in preventing recurrence, minimizing the need for repeat procedures, and extending intervals between interventions in patients with recurrent, predominantly benign airway stenosis. Its use is feasible, safe, and future research is warranted, particularly comparing PCB with the currently available strategies.